Learn about Wellbutrin SR Bupropion Hydrochloride SustainedRelease may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews. Using Wellbutrin to Stop Smoking. Wellbutrin and its competitor stop smoking drug Zyban utilize the antidepressant Bupropion, which is used to treat major depressive. Harmacologic p product guide fdaa pproved medications for smoking cessation nicotine replacement therapy nrt formulations bupropion sr varenicline. This medication can help you quit smoking by replacing the nicotine in cigarettes. The nicotine in tobacco is an important part of cigarette addiction. How To Detox Nicotine Naturally. Smoking is an addiction. Tobacco contains nicotine, a drug that is addictive. The nicotine, therefore, makes it very difficult although not impossible to quit. Wellbutrin SR Brand Name Wellbutrin SR Common Name bupropion depression In this drug factsheet How does this medication work What will it do for meZyban is a nonnicotine quit aid produced by GlaxoSmithKline. Zyban was originally marketed and prescribed under the name of Wellbutrin as an antidepressant when it. FDA prescribing information, side effects and uses. Wellbutrin bupropion hydrochloride is indicated for the treatment of major depressive disorderMDD, as defined by the Diagnostic and Statistical Manual DSM. The efficacy of Wellbutrin in the treatment of a major depressive episode was established in two 4 week controlled inpatient trials and one 6 week controlled outpatient trial of adult subjects with MDD see Clinical Studies 1. Wellbutrin Dosage and Administration. General Instructions for Use. To minimize the risk of seizure, increase the dose gradually see Warnings and Precautions 5. Increases in dose should not exceed 1. Wellbutrin Tablets should be swallowed whole and not crushed, divided, or chewed. Wellbutrin may be taken with or without food. The recommended starting dose is 2. After 3 days of dosing, the dose may be increased to 3. Dosing above 3. 00 mg per day may be accomplished using the 7. A maximum of 4. 50 mg per day, given in divided doses of not more than 1. Administer the 1. It is generally agreed that acute episodes of depression require several months or longer of antidepressant drug treatment beyond the response in the acute episode. It is unknown whether the dose of Wellbutrin needed for maintenance treatment is identical to the dose that provided an initial response. Periodically reassess the need for maintenance treatment and the appropriate dose for such treatment. Dose Adjustment in Patients with Hepatic Impairment. In patients with moderate to severe hepatic impairment Child Pugh score 7 to 1. Wellbutrin is 7. 5 mg per day. In patients with mild hepatic impairment Child Pugh score 5 to 6, consider reducing the dose andor frequency of dosing see Use in Specific Populations 8. Clinical Pharmacology 1. Dose Adjustment in Patients with Renal Impairment. Consider reducing the dose andor frequency of Wellbutrin in patients with renal impairment Glomerular Filtration Rate less than 9. L per min see Use in Specific Populations 8. Clinical Pharmacology 1. Switching a Patient to or from a Monoamine Oxidase Inhibitor MAOI Antidepressant. Beastie Boys Flac. At least 1. 4 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with Wellbutrin. Conversely, at least 1. Wellbutrin before starting an MAOI antidepressant see Contraindications 4, Drug Interactions 7. Use of Wellbutrin with Reversible MAOIs Such as Linezolid or Methylene Blue. Do not start Wellbutrin in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue. Drug interactions can increase the risk of hypertensive reactions. In a patient who requires more urgent treatment of a psychiatric condition, non pharmacological interventions, including hospitalization, should be considered see Contraindications 4, Drug Interactions 7. In some cases, a patient already receiving therapy with Wellbutrin may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of hypertensive reactions in a particular patient, Wellbutrin should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for 2 weeks or until 2. Therapy with Wellbutrin may be resumed 2. The risk of administering methylene blue by non intravenous routes such as oral tablets or by local injection or in intravenous doses much lower than 1 mg per kg with Wellbutrin is unclear. The clinician should, nevertheless, be aware of the possibility of a drug interaction with such use see Contraindications 4, Drug Interactions 7. Dosage Forms and Strengths7. Wellbutrin 7. 5. 1. Wellbutrin 1. 00. ContraindicationsWellbutrin is contraindicated in patients with a seizure disorder. Wellbutrin is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with Wellbutrin see Warnings and Precautions 5. Wellbutrin is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs see Warnings and Precautions 5. Drug Interactions 7. The use of MAOIs intended to treat psychiatric disorders concomitantly with Wellbutrin or within 1. Wellbutrin is contraindicated. There is an increased risk of hypertensive reactions when Wellbutrin is used concomitantly with MAOIs. The use of Wellbutrin within 1. MAOI is also contraindicated. Starting Wellbutrin in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated see Dosage and Administration 2. Warnings and Precautions 5. Drug Interactions 7. Wellbutrin is contraindicated in patients with known hypersensitivity to bupropion or other ingredients of Wellbutrin. Anaphylactoidanaphylactic reactions and Stevens Johnson syndrome have been reported see Warnings and Precautions 5. Warnings and Precautions. Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults. Patients with MDD, both adult and pediatric, may experience worsening of their depression andor the emergence of suicidal ideation and behavior suicidality or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of shortterm placebocontrolled trials of antidepressant drugs selective serotonin reuptake inhibitors SSRIs and others show that these drugs increase the risk of suicidal thinking and behavior suicidality in children, adolescents, and young adults ages 1. MDD and other psychiatric disorders. Short term clinical trials did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond age 2. The pooled analyses of placebo controlled trials in children and adolescents with MDD, obsessive compulsive disorder OCD, or other psychiatric disorders included a total of 2. The pooled analyses of placebocontrolled trials in adults with MDD or other psychiatric disorders included a total of 2. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger subjects for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences drug vs. These risk differences drug placebo difference in the number of cases of suicidality per 1,0. Table 1. Table 1. Risk Differences in the Number of Suicidality Cases by Age Group in the Pooled Placebo Controlled Trials of Antidepressants in Pediatric and Adult Subjects. Age Range. Drug Placebo Difference in Number of Cases of Suicidality per 1,0. Subjects Treated. Increases Compared with Placebolt 1. Decreases Compared with Placebo. No suicides occurred in any of the pediatric trials.